FFAR1 and metabolic dysfunction-associated steatotic liver disease: Furthermore, these findings support the notion of using specific GPCR agonists as an add-on therapy to manage metabolic syndrome and suggest that GPR40 merits further investigation as an adjuvant therapy for NAFLD.